Last reviewed · How we verify
Duloxetine 20 MG
Duloxetine 20 MG, marketed by Rutgers, The State University of New Jersey, is a well-established drug in the market with a key composition patent expiring in 2028. Its primary strength lies in its current market presence and the extended patent protection, which helps maintain competitive barriers. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Duloxetine 20 MG |
|---|---|
| Also known as | SNRI |
| Sponsor | Rutgers, The State University of New Jersey |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities (PHASE4)
- Home-based Transcranial Direct Current Stimulation (tDCS) Compared to Duloxetine: Non-inferiority Clinical Trial (FIBROSTIM) (NA)
- Comparing Effectiveness of Duloxetine and Desipramine in Patients With Chronic Pain: A Pragmatic Trial Using Point of Care Randomization (PHASE4)
- Pain Response Evaluation of a Combined Intervention to Cope Effectively (PHASE4)
- Identifying and Treating Depression in the Orthopaedic Trauma Population (PHASE4)
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression (PHASE3)
- A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression (PHASE3)
- A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Duloxetine 20 MG CI brief — competitive landscape report
- Duloxetine 20 MG updates RSS · CI watch RSS
- Rutgers, The State University of New Jersey portfolio CI